FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	J ,			

OMB APPROVAL

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-028
OTHER OF OTHER OLD IN BEHELLOWE OWNEROW	Estimated average burde	n
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	hours per response:	0.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Reporting Person*

2. Issuer Name **and** Ticker or Trading Symbol

Name and Address of Reporting Person* GARCIA PETER S					2. Issuer Name and Ticker or Trading Symbol PDL BIOPHARMA, INC. [PDLI]								lationship of ck all applica Director	ıble)	Perso	n(s) to Issue 10% Ow Other (s	ner
(Last) (First) (Middle) C/O PDL BIOPHARMA, INC. 932 SOUTHWOOD BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 03/28/2019						X	X Officer (give title Other (spec below) Vice President, CFO				pecity	
(Street) INCLINE VILLAGE NV 89451 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year) 04/01/2019						Line)	6. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Ta	able I - Non-I	Derivat	ive S	ecurities	Acc	quired	, Dis	posed of	f, or Ber	eficially	Owned				
Date					2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)				5. Amount Securities Beneficial Owned Fo	Form ly (D) or		Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership		
									v	Amount	(A) or (D)	Price		Reported Fransaction(s) Instr. 3 and 4)			Instr. 4)
			Table II - De			curities <i>A</i> Ils, warra							wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title an of Securit Underlyin Derivative (Instr. 3 an	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		Transaction (Instr. 4)	on(s)		
Stock Option (right to buy)	\$3.72	03/28/2019		A		641,025 ⁽¹⁾		(2)		03/28/2029	Common stock	641,025	\$0	641,02	25	D	

Explanation of Responses:

- 1. The number of shares included in the original April 1, 2019 Form 4 filing was incorrect and the Company is filing this amendment to correct the number of shares in the award grant.
- 2. The stock options will vest as follows: (a) 25% of the shares subject to the option shall vest on the one year anniversary of January 1, 2019 and (b) 75% of the shares subject to the option shall vest on a monthly basis pro rata over the thirty-six (36) months following the one year anniversary of January 1, 2019, provided that the recipient's continuous service has not terminated prior to the applicable vesting date, subject to earlier vesting upon a change in control and certain qualifying terminations of employment provided in the severance agreement between the issuer and the recipient.

Remarks:

/s/ Nathan Kryszak, Attorneyin-Fact for Peter S. Garcia

04/16/2019

In-Fact for Peter S. Garcia** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.